July 1, 2014 | Israeli bio-pharmaceutical company Red Hill Biopharma acquired Phase II oncology drug, Mesupron from Wilex AG. Mesupron has already completed a number of Phase I and Phase II clinical trials for the treatment of non-metastatic pancreatic cancer. Red Hill has acquired the exclusive development and commercialization rights for Mesupron, except in China, Hong Kong, Taiwan and Macao, for nearly $1 million from Wilex AG. The Israeli company, founded in 2009, will be responsible for the development, regulation and commercialization of Mesupron.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
UK Adopts Israeli Counter-Drone Technology
April 25, 2024
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Facebook comments